1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Yung Zip Chemical Ind. Co., Ltd.

Yung Zip Chemical Ind. Co., Ltd.

TTPEX:4102
18.75
TWD
-0.15
(-0.79%)
0.09EPS
811.46MMarket Cap
Yung Zip Chemical Ind. Co., Ltd.
TPEX:4102
(Taipei Exchange)

Recent

price

18.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
13.84
10.65
10.18
7.09
6.55
7.49
6.33
7.42
8.43
9.84
10.93
11.27
13.39
13.2
13.77
11.19
11.47
Revenue per Share
2.76
1.93
0.1
-1.58
-1.57
-0.65
-1.61
-0.59
-0.35
0.74
0.73
0.14
1.65
1.48
1.52
-0.34
-0.01
Basic EPS, GAAP
1.78
-2.96
0.09
0.04
-0.51
-0.4
0.07
-0.81
-0.09
0.38
-0.08
1.09
1.57
1.64
1.89
-1.09
-0.14
Free Cash Flow per Basic Share
0.87
1.43
1.8
0.3
- -
0.3
- -
- -
- -
- -
- -
0.1
0.1
0.8
0.8
1.22
- -
Dividend per Share
16.05
18.67
16.97
15.05
13.45
12.28
10.71
10.13
10.53
11.81
12.08
12.13
14.48
15
15.68
13.88
14.14
Book Value per Share
16.05
18.62
16.94
15.04
13.45
12.28
10.71
10.13
10.53
11.81
12.08
12.13
14.48
15
15.68
13.88
14.14
Tangible Book Value per Share
38
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
43
Basic Weighted Avg Shares
528
451
432
300
277
318
268
314
357
417
463
478
567
559
584
474
494
Sales/Revenue/Turnover
22.78
17.08
-0.19
-23.79
-26.41
-9.8
-26.22
-6.58
-6.11
5.26
6.35
1.51
8.59
10.01
10.51
-4.18
-2.94
Operating Margin (%)
38
44
58
70
60
58
58
56
50
40
38
40
38
36
32
37
40
Depreciation Expense
105
82
4
-67
-66
-28
-68
-25
-15
31
31
6
70
63
65
-14
-1
Net Income, GAAP
10.7
8.58
54.58
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.76
11.43
- -
51.08
Effective Tax Rate (%)
19.92
18.13
0.96
-22.26
-23.95
-8.71
-25.49
-7.94
-4.19
7.51
6.64
1.26
12.34
11.18
11.07
-3.03
-0.11
Profit Margin (%)
281
337
226
180
154
146
103
115
202
232
197
217
296
291
269
174
161
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
75
57
178
191
158
118
74
47
51
LT Debt
613
791
719
638
570
520
454
429
446
500
572
576
682
708
742
667
680
Total Equity
18.1
9.41
-0.07
- -
- -
- -
- -
- -
- -
4.06
- -
- -
- -
6.25
6.35
- -
-0.88
Return on Invested Capital (%)
18.93
11.33
0.55
- -
- -
- -
- -
- -
- -
5.96
- -
- -
- -
7.03
7.16
- -
-0.42
Return on Capital (%)
19.22
11.66
0.55
-9.86
-11.01
-5.07
-14.03
-5.66
-3.42
6.62
6.07
1.17
12.41
10.01
9.94
-2.29
-0.09
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
110
114
113
LT Borrowings
44
35
21
LT Finance Leases
3
32
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
42
Market Capitalization
841
818
811

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
364
362
359
Cash, Cash Equivalents & STI
95
105
90
Accounts Receivable, Net
74
65
108
Inventories
174
177
147
Total Current Liabilities
190
191
198
Payables & Accruals
- -
- -
- -
ST Debt
110
114
113
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.98%
3.52%
-10.07%
Free Cash Flow
-375.14%
-316.79%
-157.6%
Net Income, GAAP
58.81%
171.15%
-122.23%
Sales/Revenue/Turnover
4.92%
1.22%
-18.76%
Total Cash Common Dividend
- -
- -
52.32%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
150
175
157
102
584
2025
129
127
104
114
474
2026
123
153
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.64
0.7
0.33
-0.14
1.52
2025
0.02
-0.21
-0.08
-0.07
-0.34
2026
0.09
0.04
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.8
2025
- -
- -
- -
- -
1.22
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Yung Zip Chemical Ind. Co., Ltd. (4102.TWO) manufactures and supplies active pharmaceutical ingredients (APIs) including Mefenamic Acid, Diclofenac Sodium and Potassium, Acyclovir, Miconazole Nitrate and Base, Clonidine Hydrochloride, Metoprolol Succinate, Econazole Nitrate; excipients such as Sodium Starch Glycolate; API intermediates; and specialty chemicals, while providing custom research (CRO) and manufacturing (CMO) services with comprehensive chemical, manufacturing, and control (CMC) support for GMP-compliant API development and registration. Founded on June 8, 1978 and headquartered at No. 59 You Shih Road, Youth Industrial District, Dajia, Taichung City, Taiwan, the company holds international certifications from USFDA, MHRA, PMDA, KFDA, HALAL, and KOSHER, and serves global pharmaceutical customers across domestic and international markets. In recent developments, Yung Zip actively participates in major industry exhibitions including CPhI Frankfurt 2025 (booth 12.1B74), CPhI China 2026 (booth E1B55), and CPhI Milan 2024 (booth 1B122), underscoring its commitment to expanding global outreach and partnerships; the company maintains USDMF, CEP, Japan-DMF, Korea-DMF, and Canada-DMF filings for key products with the latest USFDA inspection in 2018 yielding acceptable results.